← Flowers Foods overview

Flowers Foods vs McCormick &: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Flowers Foods Inc (FLO)

Q3 2026
▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

  • Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.

    This is the core negative event that directly caused the stock to drop and reset expectations.

  • Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.

    It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.

  • Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.

    It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

September 2026
▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

  • Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.

    This is the core negative event that directly caused the stock to drop and reset expectations.

  • Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.

    It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.

  • Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.

    It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

Latest
▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

  • Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.

    This is the core negative event that directly caused the stock to drop and reset expectations.

  • Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.

    It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.

  • Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.

    It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

McCormick & Company Incorporated (MKC)

Q3 2026
▼3▲1

Unilever Deal Overhang Drives McCormick Shares Down 50%

  • Unilever deal leverage and dilution The $15.7B cash-and-stock purchase of Unilever's foods business pushes debt to 4x EBITDA and dilutes existing holders to about 35% ownership via a Reverse Morris Trust, causing shares to fall 50% from record highs.

    This is the dominant new event that explains the massive stock decline.

  • UK regulator opens probe The UK competition regulator opened an investigation into the Unilever deal, adding risk of delays or outright blockage, which weighs on investor confidence and the stock price.

    This is a new regulatory hurdle that increases uncertainty and pressures the stock.

  • Analyst downgrades on integration and share loss Analysts cut fair value and price targets, citing integration challenges, weak U.S. retail execution, and spice market share losses, which reinforced negative sentiment and contributed to the sell-off.

    These downgrades reflect new concerns that directly affect investor expectations and the stock price.

  • Strong Q3 earnings and possible Berkshire financing McCormick beat Q3 earnings expectations, reaffirmed 2026 guidance, and saw better-than-expected Flavor Solutions volume growth; possible Berkshire Hathaway financing offers a counterweight, along with a low valuation and 3.7% yield.

    These positive factors provide some support and balance the negative drivers.

September 2026
▲2▼2

McCormick's Q3 Beat Offset by Unilever Deal Risks and Analyst Caution

  • Q3 earnings beat and reaffirmed outlook McCormick reported Q3 adjusted EPS of 86 cents and revenue of $2.02 billion, both above consensus, with net sales up 17.4% and adjusted operating income of $359 million. The company reaffirmed its fiscal 2026 outlook, signaling confidence despite a tough consumer environment.

    This is the main new positive event that drove the stock up nearly 5% on the day.

  • UK regulator opens probe into Unilever Foods merger The UK Competition and Markets Authority launched an investigation into the $65 billion merger between Unilever's food business and McCormick, to assess potential harm to UK competition. The first-phase review deadline is November 11. This regulatory hurdle adds uncertainty and could delay or block the deal.

    This is a new regulatory risk that directly threatens the completion of the transformative merger.

  • Analysts cut fair value and price targets on integration and volume risks Analysts lowered McCormick's fair value to $54.85 from $60.15, with BofA trimming its target to $55 and TD Cowen downgrading to Hold with a $48 target. Concerns include weaker U.S. retail execution, share loss in spices, and risks tied to integrating the UL Foods business.

    This shows a broad reassessment of McCormick's valuation and growth prospects following the Q3 report and deal news.

  • Flavor Solutions volume growth beats expectations McCormick's Flavor Solutions segment posted 6% constant-currency sales growth in Q2, with organic growth split evenly between volume and pricing. The Americas led with 4% organic growth. Management expects this momentum to continue and drive total company volume growth for fiscal 2026.

    This is a new positive operational update that supports the growth narrative ahead of the Q3 report.

Latest
▲2▼2

McCormick's Q3 Beat Offset by Unilever Deal Risks and Analyst Caution

  • Q3 earnings beat and reaffirmed outlook McCormick reported Q3 adjusted EPS of 86 cents and revenue of $2.02 billion, both above consensus, with net sales up 17.4% and adjusted operating income of $359 million. The company reaffirmed its fiscal 2026 outlook, signaling confidence despite a tough consumer environment.

    This is the main new positive event that drove the stock up nearly 5% on the day.

  • UK regulator opens probe into Unilever Foods merger The UK Competition and Markets Authority launched an investigation into the $65 billion merger between Unilever's food business and McCormick, to assess potential harm to UK competition. The first-phase review deadline is November 11. This regulatory hurdle adds uncertainty and could delay or block the deal.

    This is a new regulatory risk that directly threatens the completion of the transformative merger.

  • Analysts cut fair value and price targets on integration and volume risks Analysts lowered McCormick's fair value to $54.85 from $60.15, with BofA trimming its target to $55 and TD Cowen downgrading to Hold with a $48 target. Concerns include weaker U.S. retail execution, share loss in spices, and risks tied to integrating the UL Foods business.

    This shows a broad reassessment of McCormick's valuation and growth prospects following the Q3 report and deal news.

  • Flavor Solutions volume growth beats expectations McCormick's Flavor Solutions segment posted 6% constant-currency sales growth in Q2, with organic growth split evenly between volume and pricing. The Americas led with 4% organic growth. Management expects this momentum to continue and drive total company volume growth for fiscal 2026.

    This is a new positive operational update that supports the growth narrative ahead of the Q3 report.

July 2026
▼2▲1

McCormick's $45B Unilever deal drives 50% share plunge and regulatory review

  • $15.7B Unilever deal crushes shares 50% on leverage fears McCormick's $15.7 billion cash-and-stock purchase of Unilever's food business pushes debt to 4x EBITDA, above its target. Investors fear the huge price paid and heavy borrowing, sending shares down 50% from record highs.

    This is the core new event explaining the massive share decline and investor concern.

  • Reverse Morris Trust structure dilutes existing shareholders The deal uses a Reverse Morris Trust, meaning McCormick issues about $29.1 billion in new shares. Unilever holders end up with roughly 65% of the combined company, leaving current McCormick owners with only 35% and heavy debt.

    Explains the mechanics of dilution that directly pressure the stock price.

  • Berkshire Hathaway interest could ease financing burden Reports suggest Berkshire's new CEO Greg Abel might invest, potentially financing the $16 billion cash need via preferred stock. McCormick's low 9x P/E and 3.7% yield make it attractive, offering a possible counterweight to the selloff.

    Provides a real positive counterweight that could support the stock if financing worries ease.

  • UK regulator opens review, adding deal uncertainty The UK competition watchdog is seeking comments on the merger until August 5. Regulatory scrutiny could delay or alter the deal, keeping a cloud over McCormick shares until the review concludes.

    New regulatory hurdle adds uncertainty that can weigh on the stock in the near term.

▼2▲1

McCormick's $45B Unilever deal drives 50% share plunge and regulatory review

  • $15.7B Unilever deal crushes shares 50% on leverage fears McCormick's $15.7 billion cash-and-stock purchase of Unilever's food business pushes debt to 4x EBITDA, above its target. Investors fear the huge price paid and heavy borrowing, sending shares down 50% from record highs.

    This is the core new event explaining the massive share decline and investor concern.

  • Reverse Morris Trust structure dilutes existing shareholders The deal uses a Reverse Morris Trust, meaning McCormick issues about $29.1 billion in new shares. Unilever holders end up with roughly 65% of the combined company, leaving current McCormick owners with only 35% and heavy debt.

    Explains the mechanics of dilution that directly pressure the stock price.

  • Berkshire Hathaway interest could ease financing burden Reports suggest Berkshire's new CEO Greg Abel might invest, potentially financing the $16 billion cash need via preferred stock. McCormick's low 9x P/E and 3.7% yield make it attractive, offering a possible counterweight to the selloff.

    Provides a real positive counterweight that could support the stock if financing worries ease.

  • UK regulator opens review, adding deal uncertainty The UK competition watchdog is seeking comments on the merger until August 5. Regulatory scrutiny could delay or alter the deal, keeping a cloud over McCormick shares until the review concludes.

    New regulatory hurdle adds uncertainty that can weigh on the stock in the near term.

Q2 2026
▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

  • Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.

    This is the main new positive event that directly lifted the stock.

  • Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.

    Guidance reaffirmation is a key new factor that gives investors confidence.

  • Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.

    This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.

June 2026
▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

  • Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.

    This is the main new positive event that directly lifted the stock.

  • Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.

    Guidance reaffirmation is a key new factor that gives investors confidence.

  • Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.

    This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.

▲2▼1

McCormick's strong Q2 earnings beat, but Unilever deal overpay concerns linger

  • Q2 earnings beat and margin expansion McCormick reported Q2 adjusted EPS of $0.80, beating estimates, with sales up 14% and gross margin expanding 270 basis points. This shows the business is performing better than expected, which pushes the stock up.

    This is the main new positive event that directly lifted the stock.

  • Reaffirmed 2026 outlook Management reaffirmed full-year adjusted EPS guidance of $3.05 to $3.13 and sales growth of 13-17%, including the Mexico acquisition. Reassuring guidance reduces uncertainty and supports the stock price.

    Guidance reaffirmation is a key new factor that gives investors confidence.

  • Unilever deal overpay concerns persist Jim Cramer said McCormick is still reeling from its acquisition of Unilever's food business, which Wall Street views as a colossal overpay. This concern weighs on the stock, as investors worry about the high price paid.

    This is a major ongoing negative force that explains why the stock remains under pressure despite good earnings.